{
"info": {
"nct_id": "NCT00996957",
"official_title": "A Phase 1 Open-Label, Multiple Dose, Dose Escalation Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma",
"inclusion_criteria": "* Diagnosis of metastatic or unresectable advanced solid tumors (solid tumors must be measurable) or relapsed/refractory multiple myeloma for which the disease has progressed despite available standard therapies or for which no standard therapy exists.\n* Life expectancy of at least 12 weeks.\n* Eastern Cooperative Oncology Group (ECOG) Performance status of 0, 1, or 2 (not declining within 2 weeks prior to study day 1).\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Central nervous system (CNS) metastases.\n* Chemotherapy or other anti-cancer therapy within 4 weeks prior to study day 1, and/or nitrosoureas within the 6 weeks prior to study day 1.\n* Lack of recovery from all toxic effects of previous chemotherapy, radiation therapy, biologic therapy, and/or experimental therapy with the exception of alopecia.\n* Radiation therapy within 4 weeks prior to study day 1.\n* Clinically significant pulmonary, cardiovascular, endocrine, neurologic, gastrointestinal or genitourinary disease unrelated to underlying solid tumor or multiple myeloma\n* Significant cardiac risk (e.g. history of myocardial infarction, unstable angina, pulmonary hypertension, clinically significant arrhythmia, congestive heart failure within 1 year prior to study day 1).\n* Diagnosis or family history of hereditary hemorrhagic telangiectasia.\n* Major surgery within 6 weeks prior to study day 1.\n* Parenteral antibiotics, or any life-threatening or active infection requiring parenteral antibiotic therapy within 1 month prior to study day 1.\n* Therapeutic anti-coagulation.\n* Uncontrolled hypertension.\n* Autoimmune or hereditary hemolysis.\n* Clinically significant gastrointestinal bleeding or any other clinically significant active bleeding within 3 months prior to study day 1.\n* Treatment with another investigational drug or device, or approved therapy for investigational use within 28 days prior to study day 1.\n* Pregnancy or lactation for female patients.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Diagnosis of metastatic or unresectable advanced solid tumors (solid tumors must be measurable) or relapsed/refractory multiple myeloma for which the disease has progressed despite available standard therapies or for which no standard therapy exists.",
"criterions": [
{
"exact_snippets": "Diagnosis of metastatic or unresectable advanced solid tumors",
"criterion": "solid tumors",
"requirements": [
{
"requirement_type": "diagnosis",
"expected_value": "metastatic or unresectable advanced"
}
]
},
{
"exact_snippets": "solid tumors must be measurable",
"criterion": "solid tumors",
"requirements": [
{
"requirement_type": "measurability",
"expected_value": true
}
]
},
{
"exact_snippets": "relapsed/refractory multiple myeloma",
"criterion": "multiple myeloma",
"requirements": [
{
"requirement_type": "status",
"expected_value": "relapsed/refractory"
}
]
},
{
"exact_snippets": "disease has progressed despite available standard therapies",
"criterion": "disease progression",
"requirements": [
{
"requirement_type": "progression despite therapy",
"expected_value": true
}
]
},
{
"exact_snippets": "no standard therapy exists",
"criterion": "standard therapy availability",
"requirements": [
{
"requirement_type": "availability",
"expected_value": false
}
]
}
]
},
{
"line": "* Life expectancy of at least 12 weeks.",
"criterions": [
{
"exact_snippets": "Life expectancy of at least 12 weeks.",
"criterion": "life expectancy",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 12,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* Eastern Cooperative Oncology Group (ECOG) Performance status of 0, 1, or 2 (not declining within 2 weeks prior to study day 1).",
"criterions": [
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) Performance status of 0, 1, or 2",
"criterion": "ECOG Performance status",
"requirements": [
{
"requirement_type": "value",
"expected_value": [
"0",
"1",
"2"
]
}
]
},
{
"exact_snippets": "not declining within 2 weeks prior to study day 1",
"criterion": "ECOG Performance status",
"requirements": [
{
"requirement_type": "stability",
"expected_value": "not declining within 2 weeks prior to study day 1"
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Central nervous system (CNS) metastases.",
"criterions": [
{
"exact_snippets": "Central nervous system (CNS) metastases",
"criterion": "CNS metastases",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Chemotherapy or other anti-cancer therapy within 4 weeks prior to study day 1, and/or nitrosoureas within the 6 weeks prior to study day 1.",
"criterions": [
{
"exact_snippets": "Chemotherapy or other anti-cancer therapy within 4 weeks prior to study day 1",
"criterion": "chemotherapy or other anti-cancer therapy",
"requirements": [
{
"requirement_type": "time since last treatment",
"expected_value": {
"operator": ">=",
"value": 4,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "nitrosoureas within the 6 weeks prior to study day 1",
"criterion": "nitrosoureas",
"requirements": [
{
"requirement_type": "time since last treatment",
"expected_value": {
"operator": ">=",
"value": 6,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* Lack of recovery from all toxic effects of previous chemotherapy, radiation therapy, biologic therapy, and/or experimental therapy with the exception of alopecia.",
"criterions": [
{
"exact_snippets": "Lack of recovery from all toxic effects of previous chemotherapy",
"criterion": "recovery from toxic effects of previous chemotherapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "Lack of recovery from all toxic effects of previous ... radiation therapy",
"criterion": "recovery from toxic effects of previous radiation therapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "Lack of recovery from all toxic effects of previous ... biologic therapy",
"criterion": "recovery from toxic effects of previous biologic therapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "Lack of recovery from all toxic effects of previous ... experimental therapy",
"criterion": "recovery from toxic effects of previous experimental therapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "with the exception of alopecia",
"criterion": "alopecia",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Radiation therapy within 4 weeks prior to study day 1.",
"criterions": [
{
"exact_snippets": "Radiation therapy within 4 weeks prior to study day 1.",
"criterion": "radiation therapy",
"requirements": [
{
"requirement_type": "time since last treatment",
"expected_value": {
"operator": "<=",
"value": 4,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* Clinically significant pulmonary, cardiovascular, endocrine, neurologic, gastrointestinal or genitourinary disease unrelated to underlying solid tumor or multiple myeloma",
"criterions": [
{
"exact_snippets": "Clinically significant pulmonary ... disease unrelated to underlying solid tumor or multiple myeloma",
"criterion": "pulmonary disease",
"requirements": [
{
"requirement_type": "significance",
"expected_value": "clinically significant"
},
{
"requirement_type": "relation to underlying condition",
"expected_value": "unrelated to underlying solid tumor or multiple myeloma"
}
]
},
{
"exact_snippets": "Clinically significant ... cardiovascular ... disease unrelated to underlying solid tumor or multiple myeloma",
"criterion": "cardiovascular disease",
"requirements": [
{
"requirement_type": "significance",
"expected_value": "clinically significant"
},
{
"requirement_type": "relation to underlying condition",
"expected_value": "unrelated to underlying solid tumor or multiple myeloma"
}
]
},
{
"exact_snippets": "Clinically significant ... endocrine ... disease unrelated to underlying solid tumor or multiple myeloma",
"criterion": "endocrine disease",
"requirements": [
{
"requirement_type": "significance",
"expected_value": "clinically significant"
},
{
"requirement_type": "relation to underlying condition",
"expected_value": "unrelated to underlying solid tumor or multiple myeloma"
}
]
},
{
"exact_snippets": "Clinically significant ... neurologic ... disease unrelated to underlying solid tumor or multiple myeloma",
"criterion": "neurologic disease",
"requirements": [
{
"requirement_type": "significance",
"expected_value": "clinically significant"
},
{
"requirement_type": "relation to underlying condition",
"expected_value": "unrelated to underlying solid tumor or multiple myeloma"
}
]
},
{
"exact_snippets": "Clinically significant ... gastrointestinal ... disease unrelated to underlying solid tumor or multiple myeloma",
"criterion": "gastrointestinal disease",
"requirements": [
{
"requirement_type": "significance",
"expected_value": "clinically significant"
},
{
"requirement_type": "relation to underlying condition",
"expected_value": "unrelated to underlying solid tumor or multiple myeloma"
}
]
},
{
"exact_snippets": "Clinically significant ... genitourinary disease unrelated to underlying solid tumor or multiple myeloma",
"criterion": "genitourinary disease",
"requirements": [
{
"requirement_type": "significance",
"expected_value": "clinically significant"
},
{
"requirement_type": "relation to underlying condition",
"expected_value": "unrelated to underlying solid tumor or multiple myeloma"
}
]
}
]
},
{
"line": "* Significant cardiac risk (e.g. history of myocardial infarction, unstable angina, pulmonary hypertension, clinically significant arrhythmia, congestive heart failure within 1 year prior to study day 1).",
"criterions": [
{
"exact_snippets": "history of myocardial infarction",
"criterion": "myocardial infarction",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "unstable angina",
"criterion": "unstable angina",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "pulmonary hypertension",
"criterion": "pulmonary hypertension",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "clinically significant arrhythmia",
"criterion": "clinically significant arrhythmia",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "congestive heart failure within 1 year prior to study day 1",
"criterion": "congestive heart failure",
"requirements": [
{
"requirement_type": "time frame",
"expected_value": {
"operator": "<=",
"value": 1,
"unit": "year"
}
}
]
}
]
},
{
"line": "* Diagnosis or family history of hereditary hemorrhagic telangiectasia.",
"criterions": [
{
"exact_snippets": "Diagnosis ... hereditary hemorrhagic telangiectasia",
"criterion": "hereditary hemorrhagic telangiectasia",
"requirements": [
{
"requirement_type": "diagnosis",
"expected_value": true
}
]
},
{
"exact_snippets": "family history of hereditary hemorrhagic telangiectasia",
"criterion": "hereditary hemorrhagic telangiectasia",
"requirements": [
{
"requirement_type": "family history",
"expected_value": true
}
]
}
]
},
{
"line": "* Major surgery within 6 weeks prior to study day 1.",
"criterions": [
{
"exact_snippets": "Major surgery within 6 weeks prior to study day 1.",
"criterion": "major surgery",
"requirements": [
{
"requirement_type": "time since surgery",
"expected_value": {
"operator": "<=",
"value": 6,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* Parenteral antibiotics, or any life-threatening or active infection requiring parenteral antibiotic therapy within 1 month prior to study day 1.",
"criterions": [
{
"exact_snippets": "Parenteral antibiotics",
"criterion": "parenteral antibiotics",
"requirements": [
{
"requirement_type": "usage",
"expected_value": false
}
]
},
{
"exact_snippets": "life-threatening or active infection requiring parenteral antibiotic therapy within 1 month prior to study day 1",
"criterion": "life-threatening or active infection",
"requirements": [
{
"requirement_type": "time frame",
"expected_value": "within 1 month prior to study day 1"
},
{
"requirement_type": "treatment requirement",
"expected_value": "parenteral antibiotic therapy"
}
]
}
]
},
{
"line": "* Therapeutic anti-coagulation.",
"criterions": [
{
"exact_snippets": "Therapeutic anti-coagulation",
"criterion": "anti-coagulation",
"requirements": [
{
"requirement_type": "purpose",
"expected_value": "therapeutic"
}
]
}
]
},
{
"line": "* Uncontrolled hypertension.",
"criterions": [
{
"exact_snippets": "Uncontrolled hypertension",
"criterion": "hypertension",
"requirements": [
{
"requirement_type": "control",
"expected_value": false
}
]
}
]
},
{
"line": "* Autoimmune or hereditary hemolysis.",
"criterions": [
{
"exact_snippets": "Autoimmune ... hemolysis",
"criterion": "autoimmune hemolysis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "hereditary hemolysis",
"criterion": "hereditary hemolysis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Clinically significant gastrointestinal bleeding or any other clinically significant active bleeding within 3 months prior to study day 1.",
"criterions": [
{
"exact_snippets": "Clinically significant gastrointestinal bleeding",
"criterion": "gastrointestinal bleeding",
"requirements": [
{
"requirement_type": "significance",
"expected_value": "clinically significant"
},
{
"requirement_type": "activity",
"expected_value": true
}
]
},
{
"exact_snippets": "any other clinically significant active bleeding within 3 months prior to study day 1",
"criterion": "active bleeding",
"requirements": [
{
"requirement_type": "significance",
"expected_value": "clinically significant"
},
{
"requirement_type": "activity",
"expected_value": true
},
{
"requirement_type": "time frame",
"expected_value": "within 3 months prior to study day 1"
}
]
}
]
},
{
"line": "* Treatment with another investigational drug or device, or approved therapy for investigational use within 28 days prior to study day 1.",
"criterions": [
{
"exact_snippets": "Treatment with another investigational drug or device",
"criterion": "treatment with investigational drug or device",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "approved therapy for investigational use within 28 days prior to study day 1",
"criterion": "approved therapy for investigational use",
"requirements": [
{
"requirement_type": "time since last treatment",
"expected_value": {
"operator": ">=",
"value": 28,
"unit": "days"
}
}
]
}
]
},
{
"line": "* Pregnancy or lactation for female patients.",
"criterions": [
{
"exact_snippets": "Pregnancy",
"criterion": "pregnancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "lactation for female patients",
"criterion": "lactation",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}